OPKO Health Sells Assets to Labcorp for Up to $872 Million
Translated & summarized from Ice by baba
OPKO Health is selling selected assets of its subsidiary BioReference Health to Labcorp for $722 million in cash plus up to $150 million in contingent payments. The deal includes the proprietary 4Kscore prostate cancer test and is expected to boost OPKO's focus on biopharmaceuticals. Following the announcement, OPKO's stock surged over 25% on the Tel Aviv Stock Exchange. The transaction is subject to regulatory approvals.
The story in 6 lines · by baba
- OPKO Health will sell BioReference Health assets to Labcorp for $722 million cash and up to $150 million contingent.
- The deal includes the 4Kscore prostate cancer test, with Labcorp's network expanding its reach.
- OPKO's stock jumped 25.64% following the announcement of the strategic asset sale.
- The sale aims to streamline OPKO's structure and focus resources on biopharmaceutical development.
- The transaction is pending regulatory approvals and customary closing conditions.
- OPKO's Q2 2026 revenues reached $163.5 million, surpassing analyst expectations.
Biopharmaceutical company OPKO Health has entered into a significant strategic agreement to sell selected assets of its subsidiary, BioReference Health, to the American laboratory services giant Labcorp. The deal is structured to provide OPKO with $722 million in cash upon completion, subject to adjustments. Additionally, OPKO could receive up to $150 million in contingent consideration tied to future revenues from the 4Kscore test, a proprietary blood test for early prostate cancer detection that is also part of the sale. The acquired assets encompass a broad range of clinical testing services in women's health, urology, and correctional facilities, along with over 80 patient service centers. Labcorp anticipates the divested operations will generate approximately $250 million in revenue in the first year post-closing.
This strategic move, spearheaded by OPKO Chairman and CEO Dr. Philip Frost, aims to unlock shareholder value and streamline the company's organizational structure. The objective is to refocus resources on developing OPKO's biopharmaceutical business. The transaction is contingent upon regulatory approvals and customary closing conditions. Until the deal is finalized, both companies will continue to operate independently.
Following the announcement, OPKO Health's stock experienced a substantial surge, closing the trading day with a 25.64% increase on the Tel Aviv Stock Exchange, reaching a price of 512 agorot. Beyond the immediate cash infusion, the deal offers long-term potential for OPKO through the contingent payment mechanism, particularly linked to the success of the FDA-approved 4Kscore test. This test aids in assessing the likelihood of aggressive prostate cancer, helping to inform decisions before invasive biopsies.
Labcorp's extensive national network in the United States is expected to significantly broaden access to the 4Kscore test for physicians and patients, enhancing medical care and boosting revenue potential. This expansion will allow OPKO to benefit from the test's future commercial success as per the agreement's terms. In its second quarter 2026 financial reports, OPKO Health reported revenues of $163.5 million, a 4.3% increase from the previous year and exceeding analyst expectations of around $131 million.
